Renaissance Capital logo

NVCR News

Cancer zapping device company Pulse Biosciences prices IPO at $4, as expected

NovoCure logo

Pulse Biosciences, which is developing treatments for solid tumors based on pulsed electric fields, raised $20 million by offering 5 million shares at $4, as expected. At $4 per share, Pulse commands a diluted market cap of $51 million. ...read more

US IPO Weekly Recap: Only five deals get done after massive valuation cuts

CERCU

Home, home below the range: all five deals this week priced below the range.  There were eleven companies on the IPO calendar this week, but only five were ...read more

NovoCure prices IPO at $22, below the downwardly revised range

NovoCure logo

NovoCure, which markets a wearable electric field device for treating glioblastoma brain cancer, raised $165 million by offering 7.5 million shares (all primary) at $22, below the downwardly revised range of $23 to $24. The company originally planned to offer 12...read more

NovoCure slashes range and removes insider selling ahead of $176 million IPO

NovoCure logo

NovoCure, which markets a wearable electric field device for treating glioblastoma brain cancer, slashed its range and removed insider selling ahead of its upcoming IPO on Thursday. The St Helier, Jersey-based company now plans to raise $176 million by...read more